![Gregory Perry](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Gregory Perry
Direttore Finanziario/CFO presso
MERUS N.V.
Patrimonio netto: 312 $ in data 31/05/2026
Profilo
Gregory D.
Perry is currently Director at Oculis Holding AG since 2026 and Chief Financial Officer at Merus NV since 2023.
Formerly, served as Independent Director at Kala Bio, Inc. from 2018 to 2025; Chief Financial Officer at Finch Therapeutics Group, Inc. from 2018 to 2022; Chief Financial & Administrative Officer at Novelion Therapeutics, Inc. in 2017; Chief Financial & Administrative Officer at Aegerion Pharmaceuticals, Inc. in 2016; Independent Director at Astellas Institute for Regenerative Medicine from 2012 to 2016; Chief Financial & Business Officer at Sesen Bio, Inc. from 2014 to 2015; Director at rEVO Biologics, Inc. in 2014; Chief Financial Officer at Invivo Therapeutics Holdings Corp.
in 2013; Chief Financial Officer, Treasurer & Executive VP at ImmunoGen, Inc. from 2011 to 2013; Chief Financial Officer & Executive Vice President at Elixir Pharmaceuticals, Inc. from 2007 to 2008; Chief Financial Officer at Domantis Ltd. in 2006; Chief Financial Officer & Senior Vice President at Transkaryotic Therapies, Inc. from 2003 to 2005; SVP-Finance, Business Development & Life Sciences at Revvity, Inc.; and Chief Financial Officer & Vice President at GE Medical Systems, Inc. Education includes undergraduate degree from Amherst College.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 15/06/2025 | 140 ( 0% ) | 312 $ | 31/05/2026 |
Posizioni attive di Gregory Perry
| Società | Posizione | Inizio |
|---|---|---|
| MERUS N.V. | Direttore Finanziario/CFO | 14/06/2023 |
| OCULIS HOLDING AG | Direttore/Membro del Consiglio | 13/05/2026 |
Precedenti posizioni note di Gregory Perry
| Società | Posizione | Fine |
|---|---|---|
| KALA BIO, INC. | Direttore/Membro del Consiglio | 23/11/2025 |
| FINCH THERAPEUTICS GROUP, INC. | Direttore Finanziario/CFO | 30/04/2022 |
| NOVELION THERAPEUTICS INC. | Direttore Finanziario/CFO | 31/12/2017 |
| AEGERION PHARMACEUTICALS, INC. | Direttore Finanziario/CFO | 01/11/2016 |
| OCATA THERAPEUTICS INC | Direttore/Membro del Consiglio | 10/02/2016 |
Formazione di Gregory Perry
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
58
Relazioni di 1° grado
17
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 17 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Develops and markets biopharmaceutical products | Commercial Services |
Revvity, Inc.
 Revvity, Inc. Medical SpecialtiesHealth Technology Manufactures and distributes reagents, analytical instruments and develops software | Health Technology |
Domantis Ltd.
 Domantis Ltd. Pharmaceuticals: MajorHealth Technology Develops domain antibody therapeutics for treating highly unmet diseases | Health Technology |
Aegerion Pharmaceuticals, Inc.
 Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and commercializes therapies for hyperlipidemia and metabolic diseases | Health Technology |
Kala Bio, Inc.
 Kala Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company developing mesenchymal stem cell secretive (MSC-S) therapies | Health Technology |
GE Medical Systems, Inc.
 GE Medical Systems, Inc. Medical SpecialtiesHealth Technology Manufactures diagnostic imaging and medical monitoring systems as well as provides information technology services to health care providers | Health Technology |
Elixir Pharmaceuticals, Inc.
 Elixir Pharmaceuticals, Inc. Investment Trusts/Mutual FundsMiscellaneous Operates as a holding company with interest in manufacturing and developing biopharmaceutical products for the treatment of metabolic diseases | Miscellaneous |
Amherst College
 Amherst College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Astellas Institute for Regenerative Medicine
 Astellas Institute for Regenerative Medicine Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine | Health Technology |
Merus NV
 Merus NV BiotechnologyHealth Technology Discovers and develops therapeutics for cancer treatment | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops protein therapeutics to treat eye diseases | Health Technology |
Invivo Therapeutics Holdings Corp.
 Invivo Therapeutics Holdings Corp. BiotechnologyHealth Technology Develops technologies for the treatment of spinal cord injuries | Health Technology |
rEVO Biologics, Inc.
 rEVO Biologics, Inc. BiotechnologyHealth Technology Develops and commercializes specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions | Health Technology |
Novelion Therapeutics, Inc.
 Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets rare disease products, metreleptin and lomitapide | Health Technology |
Finch Therapeutics Group, Inc.
 Finch Therapeutics Group, Inc. Medical/Nursing ServicesHealth Services Provides microbial therapy services | Health Services |
Oculis Holding AG
 Oculis Holding AG Miscellaneous Commercial ServicesCommercial Services Operates as a global biopharmaceutical company that develops novel therapeutics to treat ophthalmic diseases | Commercial Services |
